"Varenicline" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A benzazepine derivative that functions as an ALPHA4/BETA2 NICOTINIC RECEPTOR partial agonist. It is used for SMOKING CESSATION.
| Descriptor ID |
D000068580
|
| MeSH Number(s) |
D03.633.100.079.900 D03.633.100.857.942
|
| Concept/Terms |
Varenicline- Varenicline
- 6,7,8,9-Tetrahydro-6,10-methano-6H-pyrazino(2,3-h)benzazepine
|
Below are MeSH descriptors whose meaning is more general than "Varenicline".
Below are MeSH descriptors whose meaning is more specific than "Varenicline".
This graph shows the total number of publications written about "Varenicline" by people in this website by year, and whether "Varenicline" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
| 2022 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Varenicline" by people in Profiles.
-
A Psychometric Evaluation of the Stanford Expectations of Treatment Scale (SETS) in the Context of a Smoking Cessation Trial. Nicotine Tob Res. 2022 Nov 12; 24(12):1914-1920.
-
Evaluating Treatment Mechanisms of Varenicline: Mediation by Affect and Craving. Nicotine Tob Res. 2022 10 26; 24(11):1803-1810.
-
The impact of three weeks of pre-quit varenicline on reinforcing value and craving for cigarettes in a laboratory choice procedure. Psychopharmacology (Berl). 2021 Feb; 238(2):599-609.
-
Varenicline is a potent partial agonist at a6ß2* nicotinic acetylcholine receptors in rat and monkey striatum. J Pharmacol Exp Ther. 2012 Aug; 342(2):327-34.
-
Culturally-tailored smoking cessation for American Indians: study protocol for a randomized controlled trial. Trials. 2011 May 18; 12:126.
-
An employer-based cost-benefit analysis of a novel pharmacotherapy agent for smoking cessation. J Occup Environ Med. 2007 Apr; 49(4):453-60.